A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study

When combined with early and specific restoration of hemostatic reserves after cardiac surgery, very low-dose recombinant activated factor VII treatment of refractory bleeding is effective and not associated with any apparent increase in adverse events.